A detailed history of Driehaus Capital Management LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Driehaus Capital Management LLC holds 5,885,248 shares of CRNX stock, worth $326 Million. This represents 2.95% of its overall portfolio holdings.

Number of Shares
5,885,248
Previous 6,112,173 3.71%
Holding current value
$326 Million
Previous $274 Million 9.81%
% of portfolio
2.95%
Previous 2.95%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$43.83 - $54.98 $9.95 Million - $12.5 Million
-226,925 Reduced 3.71%
5,885,248 $301 Million
Q2 2024

Aug 14, 2024

BUY
$42.12 - $51.91 $37.3 Million - $46 Million
885,876 Added 16.95%
6,112,173 $274 Million
Q1 2024

May 15, 2024

BUY
$34.76 - $46.81 $6.48 Million - $8.72 Million
186,340 Added 3.7%
5,226,297 $245 Million
Q4 2023

Feb 14, 2024

SELL
$25.62 - $37.07 $2.37 Million - $3.42 Million
-92,330 Reduced 1.8%
5,039,957 $179 Million
Q3 2023

Nov 14, 2023

SELL
$15.97 - $30.59 $2.65 Million - $5.07 Million
-165,801 Reduced 3.13%
5,132,287 $153 Million
Q2 2023

Aug 14, 2023

BUY
$15.73 - $23.6 $134,790 - $202,228
8,569 Added 0.16%
5,298,088 $95.5 Million
Q1 2023

May 15, 2023

SELL
$15.31 - $21.1 $5.13 Million - $7.07 Million
-335,225 Reduced 5.96%
5,289,519 $84.9 Million
Q4 2022

Feb 14, 2023

SELL
$15.49 - $19.05 $111,744 - $137,426
-7,214 Reduced 0.13%
5,624,744 $103 Million
Q3 2022

Nov 14, 2022

BUY
$18.11 - $22.37 $2.85 Million - $3.52 Million
157,499 Added 2.88%
5,631,958 $111 Million
Q2 2022

Aug 15, 2022

BUY
$16.49 - $27.64 $8.75 Million - $14.7 Million
530,446 Added 10.73%
5,474,459 $102 Million
Q1 2022

May 16, 2022

BUY
$17.15 - $28.31 $2.58 Million - $4.26 Million
150,375 Added 3.14%
4,944,013 $109 Million
Q4 2021

Feb 14, 2022

BUY
$19.35 - $28.41 $34.7 Million - $51 Million
1,795,126 Added 59.87%
4,793,638 $136 Million
Q3 2021

Nov 15, 2021

BUY
$16.88 - $25.23 $4.91 Million - $7.33 Million
290,687 Added 10.74%
2,998,512 $63.1 Million
Q2 2021

Aug 16, 2021

BUY
$15.9 - $21.15 $11.2 Million - $14.9 Million
704,137 Added 35.14%
2,707,825 $51 Million
Q1 2021

May 17, 2021

BUY
$13.3 - $17.55 $7.31 Million - $9.65 Million
549,722 Added 37.81%
2,003,688 $30.6 Million
Q4 2020

Feb 16, 2021

BUY
$12.08 - $17.46 $7 Million - $10.1 Million
579,124 Added 66.2%
1,453,966 $20.5 Million
Q3 2020

Nov 16, 2020

SELL
$13.62 - $17.66 $162,350 - $210,507
-11,920 Reduced 1.34%
874,842 $13.7 Million
Q2 2020

Aug 14, 2020

BUY
$13.04 - $23.23 $11.6 Million - $20.6 Million
886,762 New
886,762 $15.5 Million

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.98B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Driehaus Capital Management LLC Portfolio

Follow Driehaus Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Driehaus Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Driehaus Capital Management LLC with notifications on news.